Obalon Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>OT</div>
OBLN -- USA Stock  

USD 3.71  0.29  7.25%

Obalon Therapeutics Working Capital is quite stable at the moment as compared to the past year. The company's current value of Working Capital is estimated at 18.58 Million. PPandE Turnover is expected to rise to 2.75 this year, although the value of Net Income Per Employee will most likely fall to (864 K). This short post will outline Obalon Therapeutics as a possible investment alternative for your portfolios. We will provide a perspective on Obalon Therapeutics future direction.
Published over a month ago
View all stories for Obalon Therapeutics | View All Stories
Our latest forecast of Obalon (NASDAQ:OBLN)
Obalon Therapeutics is OVERVALUED at 4.52 per share with modest projections ahead. About 44.0% of Obalon Therapeutics shares are owned by institutional investors. Insiders ownership of Obalon Therapeutics refers to the amount of Obalon Therapeutics equity owned by Obalon officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Obalon, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Obalon Therapeutics. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Obalon Therapeutics

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Obalon Therapeutics' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Obalon Therapeutics in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Obalon Therapeutics. Your research has to be compared to or analyzed against Obalon Therapeutics' peers to derive any actionable benefits. When done correctly, Obalon Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Obalon Therapeutics.

How important is Obalon Therapeutics's Liquidity

Obalon Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Obalon Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Obalon Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Obalon Therapeutics's total debt and its cash.

How Obalon utilizes its cash?

To perform a cash flow analysis of Obalon Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Obalon Therapeutics is receiving and how much cash it distributes out in a given period. The Obalon Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Obalon Therapeutics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (28.37 Million)

Acquisition by William Plovanic of 27250 shares of Obalon Therapeutics subject to Rule 16b-3

Legal trades by Obalon Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Obalon insider trading alert for grant of stock option (right to buy) by William Plovanic, the corporate stakeholder, on 18th of September 2020. This event was filed by Obalon Therapeutics Inc with SEC on 2020-09-18. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper look at Obalon

Obalon Therapeutics is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Obalon Therapeutics implied risk.

Returns Breakdown

Return on Investment(148.25)
Return on Assets(0.95)
Return on Equity(1.81)
Return Capital(7.31)
Return on Sales(6.89)

Another 3 percent rise for Obalon Therapeutics

The mean deviation is down to 16.79 as of today. As of the 23rd of January, Obalon Therapeutics holds the Coefficient Of Variation of 716.05, risk adjusted performance of 0.1453, and Semi Deviation of 6.56. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Obalon Therapeutics, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Obalon Therapeutics, which can be compared to its competitors. Please check Obalon Therapeutics standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Obalon Therapeutics is priced some-what accurately, providing market reflects its current price of 6.02 per share. Given that Obalon Therapeutics has jensen alpha of 7.71, we recommend you to check out Obalon Therapeutics's recent market performance to make sure the company can sustain itself at a future point.

The Bottom Line

Whereas some firms within the medical devices industry are still a little expensive, even after the recent corrections, Obalon Therapeutics may offer a potential longer-term growth to institutional investors. While some institutional investors may not share our view we believe it may be a good time to drop Obalon as the risk-reward trade off is not appealing enough to hold a position. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Obalon Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Obalon Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com